{
  "id": 15877887,
  "title": "Psyence BioMed Completes PsyLabs Investment as Ibogaine Milestones Are Met",
  "url": "https://urgent.news/2026/10/21/psyence-biomed-completes-psylabs-investment-as-ibogaine-milestones",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-21T11:12:29.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/psyence-biomed-completes-psylabs-investment-as-ibogaine-milestones-are-met"
  },
  "original_language": "en",
  "account": null,
  "summary": "Ibogaine regulatory readiness pack completed and U.S. cGMP manufacturing agreement concluded with DEA-registered Benuvia in Texas; investment supports PsyLabs’ intended supply of pharmaceutical-grade ibogaine for the planned U.S. development program NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today announced that both…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}